<DOC>
	<DOCNO>NCT01879332</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , sequential multiple ascend dose study determine maximum tolerate dose</brief_summary>
	<brief_title>A Sequential Multiple Ascending Dose Study Safety Pharmacokinetics Eslicarbazepine Acetate Adult Healthy Volunteers</brief_title>
	<detailed_description>This study design randomize , double-blind , placebo-controlled , sequential multiple ascend dose study assess safety pharmacokinetics supratherapeutic dos eslicarbazepine acetate 32 healthy adult male female subject , 8 subject per treatment group . In study group , subject receive single dos eslicarbazepine acetate placebo daily 5 day . A series screen evaluation perform within 21-day period prior first dose study medication order determine eligibility prospective study participant trial . Eligible subject report clinic Day -1 prior study medication administration remain clinic clinic discharge Day 7 . Plasma urine sample collect throughout study determine pharmacokinetics eslicarbazepine acetate metabolite .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Healthy male female 18 45 year age . Women require postmenopausal ( 12 month since last period ) ; surgically sterile ( hysterectomy tubal ligation least 6 month prior enrollment ) ; use intrauterine device ; double barrier ( i.e . diaphragm spermicide plus male condom ) nonhormonal contraceptive therapy duration trial . Female subject require negative pregnancy test screen upon checkin study facility . BMI within range 1830 kg/m2 . Ability communicate effectively study personnel . No significant disease abnormal laboratory value determine medical history , physical examination laboratory evaluation , conduct screen visit admission clinic . Normal 12lead electrocardiogram , without clinically significant abnormality rate , rhythm conduction . Nonsmokers define smoke past 6 month . Subjects adequately informed nature risk study require provide write informed consent prior study entry . Known hypersensitivity allergy eslicarbazepine acetate relate compound carbamazepine , oxcarbazepine , licarbazepine . Women pregnant breast feeding . Any disease condition ( medical surgical ) , opinion investigator , potential compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition could interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk . A sustained supine systolic blood pressure &gt; 140 mmHg &lt; 100mmHg diastolic blood pressure &gt; 95 mmHg screen baseline . A rest ECG heart rate &lt; 50 bpm &gt; 100 bpm . An abnormal screening ECG indicate second thirddegree AV block , one following : QRS &gt; 110 millisecond ( msec ) , QTc ( Fridericia correction ) &gt; 450 msec , PR interval &gt; 240 msec . Any rhythm sinus rhythm , interpret Investigator clinically significant . The presence abnormal laboratory value consider clinically significant . Positive screen Hepatitis B ( HbsAg , Hepatitis B Surface Antigen ) , Hepatitis C ( anti HCV , Hepatitis C Antibody ) , HIV ( antiHIV 1 2 ) . Receipt investigational drug within period 30 day prior enrollment study . Receipt drug therapy , include hormonal contraceptive , within 2 week prior administration first dose studyrelated treatment . This exclusion extend 4 week drug know induce inhibit hepatic drug metabolism . Consumption alcohol within 48 hour prior dose administration inpatient period . A positive urine drug screen include ethanol , cocaine , THC , barbiturates , amphetamine , benzodiazepine , opiate . Any history alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction . A history difficulty donate blood . Donation blood blood product within 45 day prior enrollment . Subjects , history , additional risk factor Torsades de Points ( e.g. , heart failure , hypokalemia ) , family history long QT syndrome family history sudden death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Anticonvulsant</keyword>
</DOC>